A
ApnimedClinical-stage biotech developing Oxnimbi (AD109), the first investigational oral pill for obstructive sleep apnea.
3 Pulse stories
CB
Colossal BiosciencesColossal Biosciences is a genetic engineering company working to de-extinct species like the woolly mammoth and dire wolf while commercializing spinout biotech applications.
2 Pulse stories
Total Raised
$850M
ApnimedColossal Biosciences
Last Valuation
$10.3B
ApnimedColossal Biosciences
Biotech
Sector
Biotech
2017
Founded
2021
Cambridge, Massachusetts
HQ
Dallas, Texas
Public (APMD)
Status
Private
Apnimed investors
ShionogiColumbia Seligman Technology and Information FundAlpha Wave GlobalMorningside VenturesColumbia ManagementNexPoint Asset ManagementSectoral Asset Management
Colossal Biosciences investors
TWG GlobalThomas TullMark WalterTim DraperWinklevoss CapitalIn-Q-TelARCH Venture PartnersTom Brady
Data from Value Add Pulse coverage and company research — see the full threads for Apnimed and Colossal Biosciences.